Significant Advances in Chronic Bronchitis Treatment Featured in Pivotal RejuvenAir® Trial Publication

Pivotal SPRAY-CB Trial Results

In a groundbreaking release, CSA Medical, Inc. has published the results of the SPRAY-CB trial in the American Journal of Respiratory and Critical Care Medicine. This pivotal study evaluated the effectiveness of the Metered CryoSpray™ therapy using the RejuvenAir® System in patients suffering from moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis. 210 patients from the US and UK participated in this randomized, controlled trial, experiencing significant respiratory symptoms despite receiving optimal standard of care treatments.

Upon evaluating the results after one year, those treated with the Metered CryoSpray demonstrated a noteworthy improvement of 5.9 points on the St. George's Respiratory Questionnaire (SGRQ), compared to the control group, surpassing the 4-point threshold deemed clinically significant with a p-value of 0.0422. Similarly, there was a 3.4-point enhancement on the COPD Assessment Test (CAT) indicating better symptom management and quality of life overall, as evidenced by a p-value of 0.005. These findings highlight the potential of MCS therapy in delivering not just symptomatic relief but also improvements in patient well-being.

The trial also uncovered a remarkable 38.4% relative reduction in severe COPD exacerbation rates among patients treated with MCS compared to the control group. Severe exacerbations are critical as they significantly contribute to healthcare burdens, often necessitating emergency interventions or hospital admissions. Lead investigator Dr. Gerard J. Criner emphasizes the dire need for effective treatments in chronic bronchitis, where many patients face an uphill battle with their symptoms even while adhering strictly to prescribed therapies.

Dr. Criner's findings emphasize that the introduction of Metered CryoSpray could revolutionize the management of chronic bronchitis, addressing a significant gap in treatment options. The rigorous and methodologically sound design of this randomized, sham-controlled trial provides strong evidence to suggest the RejuvenAir System could be a groundbreaking therapy that targets the airways directly, relieving the symptoms of chronic bronchitis more effectively than existing medications.

Following more than ten years of research and clinical studies, CSA Medical's RejuvenAir System has been designed to offer patients hope through its minimally invasive bronchoscopic approach that ensures targeted intervention on affected airway epithelium. This approach not only alleviates symptoms but also supports the healing of the affected tissues. The therapy involves delivering measured doses of medical-grade liquid nitrogen, which is intended to foster a healing process without causing scar tissue formation, promoting healthier airway function.

Importantly, despite the promising benefits, MCS presents with acceptable safety profiles, with the primary risk of pneumothorax occurring in about 3.6% of procedures, all of which resolved without complications after discharge. This positive safety affirmation resonates well with clinicians and highlights the therapy's viability as an innovative option for individuals grappling with chronic bronchitis.

The RejuvenAir System has also obtained FDA Breakthrough Device Designation, showcasing its potential to surpass existing treatments and fill critical needs in an underserved patient community. CSA Medical remains committed to its aim of transforming chronic bronchitis management, with ongoing FDA review processes underway for this innovative device.

Understanding Chronic Bronchitis

Chronic bronchitis falls under COPD and is characterized by chronic cough and mucus overproduction, leading to significant discomfort and decreased quality of life for patients. In the United States alone, nearly 16 million individuals are estimated to suffer from COPD, with over 9 million having chronic bronchitis, illustrating the urgent necessity for effective treatment alternatives.

Conclusion

With the publication of the SPRAY-CB trial outcomes, CSA Medical's RejuvenAir offers a ray of hope for chronic bronchitis patients, paving the way for enhanced symptom management and improved quality of life. As research continues to evolve, the RejuvenAir System may soon transform the therapeutic landscape for those affected by this challenging condition.